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Abstract Previous studies have demonstrated that low
density lipoprotein cholesterol (LDL-C) concentration is
influenced by both genes and environment. Although rare
genetic variants associated with Mendelian causes of in-
creased LDL-C are known, only one common genetic variant
has been identified, the apolipoprotein E gene (APOE). In an
attempt to localize quantitative trait loci (QTLs) influencing
LDL-C, we conducted a genome-wide linkage scan of LDL-C
in participants of the Strong Heart Family Study (SHFS).
Nine hundred eighty men and women, age 18 years or older,
in 32 extended families at three centers (in Arizona,
Oklahoma, and North and South Dakota) were phenotyped
for LDL-C concentration and other risk factors. Using a
variance component approach and the programSOLAR, and
after accounting for the effects of covariates, we detected a
QTL influencing LDL-C on chromosome 19, nearest marker
D19S888 at 19q13.41 [logarithm of odds (LOD)5 4.3] in the
sample from the Dakotas. This region on chromosome
19 includes many possible candidate genes, including the
APOE/C1/C4/C2 gene cluster. In follow-up association ana-
lyses, no significant evidence for an association was de-
tected with the APOE*«2 and APOE*«4 alleles (P5 0.76 and
P 5 0.53, respectively). Suggestive evidence of linkage to
LDL-C was detected on chromosomes 3q, 4q, 7p, 9q, 10p,
14q, and 17q. These linkage signals overlap positive
findings for lipid-related traits and harbor plausible candi-
date genes for LDL-C.—North, K. E., H. H. H. Göring, S. A.
Cole, V. P. Diego, L. Almasy, S. Laston, T. Cantu, B. V. Howard,
E. T. Lee, L. G. Best, R. R. Fabsitz, and J. W. MacCluer. Linkage
analysis of LDL cholesterol in American Indian populations:
the Strong Heart Family Study. J. Lipid Res. 2006. 47: 59–66.
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Low density lipoprotein cholesterol (LDL-C) is a strong
independent predictor of cardiovascular disease, because
it is the most important contributor of cholesteryl ester to
atherosclerotic plaque (1). It is well established that ge-
netic factors contribute to the variability in LDL-C concen-
tration. The structural gene for apolipoprotein B (APOB),
the apolipoprotein in LDL-C, and the LDL receptor gene,
a key regulator of plasma LDL-C concentrations, have been
isolated and sequenced. Four monogenic diseases [familial
hypercholesterolemia (2), familial ligand-defective apoB-
100 (3), sitosterolemia (4), and autosomal recessive hyper-
cholesterolemia (5)] have been identified that cause
hyperlipidemia by impairing the activity of hepatic LDL-C
receptors, which function to remove LDL-C from the plas-
ma (6). In addition, various other candidate genes encod-
ing proteins from the lipid metabolism pathway have been
associated with variation in lipid levels, yet the magnitude
of each polymorphism’s effect is generally small in a given
population (7).
Strong aggregate genetic effects on LDL-C variability
have been recognized across multiple populations (8–11),
although the identification of specific variants has been
lacking. One possible exception is the common variant in
the structural apolipoprotein E gene (APOE), which has
been consistently associated with LDL-C variation across
multiple populations but accounts for ,10% of the total
phenotypic variance (12, 13). Interactions between the
APOE polymorphisms and environmental modulators, par-
ticularly nutrient intake, have also been indicated (14).
Other relevant polymorphisms in the APOE gene pro-
moter region (2219G/T and 1113G/C) have also been
evaluated, but the findings from these studies have been
inconsistent (15–18).
Genome-wide linkage scans have been performed to
identify regions of the genome harboring genes that reg-
ulate cholesterol concentrations, but the identification of
quantitative trait loci (QTLs) has been challenging. Bosse
et al. (19) recently published a compendium of genome-
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wide scans of lipid-related phenotypes, which identified 11
genome scans of LDL-C. Two more genome scans of LDL-
C have been published recently (20, 21), and as is the case
with most common complex diseases, several regions of
the genome have been implicated, perhaps suggesting
locus heterogeneity. To advance our knowledge of the ge-
netic factors influencing LDL-C, more studies are needed
because replication of existing QTLs in independent
samples is essential. Thus, in an attempt to localize new
QTLs influencing LDL-C and/or to provide new evidence
in support of previously identified QTLs, we conducted a




The Strong Heart Study (SHS) began in 1988 to investigate
cardiovascular disease and its risk factors in a geographically
diverse group of resident American Indian tribal members aged
45 to 74 years at three study centers in Arizona, Oklahoma, and
North and South Dakota. The SHFS, a component of the SHS,
was initiated in 1996 with the goal of localizing genes that
influence risk factors for clinical and subclinical cardiovascular
disease, diabetes, and obesity and their progression over time. In
the first phase of the SHFS, completed in September 1999, at
least 300 members of 9–12 extended families were recruited and
examined in each of the three centers in Arizona, South Dakota,
and Oklahoma. In the second phase of the family study, initiated
in 2001, an additional 900 family members in each center were
recruited and examined, for a total of .3,600 men and women in
multiple extended families. This study focuses on participants
from the first phase of the family study, for which phenotypic and
genotypic data are complete. Detailed descriptions of the SHS
and SHFS study design and laboratory protocols have been pub-
lished (22). The SHS and SHFS protocols were approved by the
Indian Health Service Institutional Review Board, by the insti-
tutional review boards of the participating institutions, and by the
13 American Indian tribes participating in these studies.
Phenotypic and genotypic data
Phenotypic data. Standard protocols were used for the collec-
tion of all data and are described in detail in previous pub-
lications (23). During a personal interview, information on the
following demographic characteristics was obtained by question-
naire: income, residence, marital status, number of household
members, tribal enrollment, degree of Indian heritage, educa-
tion, and other cultural factors. Participants were asked lifestyle
questions, with a focus on smoking, alcohol intake, and physical
activity. For questions on alcohol intake, current and ever drink-
ing were defined as having had at least one alcoholic beverage in
the last year and/or lifetime, respectively. Smoking was defined
as having had at least 100 cigarettes. Physical activity was mea-
sured using metabolic equivalents (METs), where 1 MET is equal
to a resting oxygen consumption of z3.5 ml/kg/min. A repro-
ductive history was taken that included questions concerning
parity, gravidity, menopausal status, and estrogen use.
Fasting blood samples were obtained during the physical
examination and assayed at MedStar Research Institute using
standard laboratory methods as described previously (23). Tri-
glycerides, total cholesterol, and HDL-C were measured using
enzymatic reagents and the Hitachi 717. LDL-C was derived using
the Friedewald equation; it was directly measured in subjects with
triglyceride values of .400 mg/dl (24). Glucose was measured by
the hexokinase method (Glucose-HK; BMD, Inc.) on the Hitachi
717. Type II diabetes, impaired fasting glucose, and normal
glucose tolerance status were determined according to American
Diabetes Association criteria (25). As described previously (26),
APOE phenotype was determined in whole plasma using a mod-
ification of the method of Kamboh, Ferrell, and Kottke (27), in
which 2 h of isoelectric focusing are followed by immunoblotting
to visualize the APOE bands.
Genotypic data. The SHFS genotyping procedures have been
documented (V. G. Diego, H. H. H. Göring, S. Cole, L. Almasy,
and K. E. North, unpublished data). In brief, DNA was isolated
from fasting blood samples using organic solvents and then
amplified in separate PCR procedures with primers specific for
short tandem repeat markers using the ABI PRISM Linkage
Mapping Set-MD10 version 2.5 (Applied Biosystems, Foster City,
CA). PCR products were loaded into an ABI PRISM 377 DNA
sequencer for laser-based automated genotyping. Analyses and
assignment of the marker alleles were done using computerized
algorithms (Applied Biosystems).
We used sex-averaged chromosomal maps obtained from
the Marshfield Center for Medical Genetics (http://research.
marshfieldclinic.org/genetics). All genetic distances are reported
in Haldane centimorgans (cM). Pedigree relationships were ver-
ified using the PREST (Pedigree Relationship Statistical Tests)
package (28), which uses likelihood-based inference statistics for
genome-wide identity-by-descent allele sharing. Mendelian incon-
sistencies and spurious double recombinants were detected using
the SimWalk2 package (29). The overall blanking rate for both
types of errors was ,1% of the total number of genotypes for
Arizona, North and South Dakota, and Oklahoma. We used the
web resources of the University of California Santa Cruz (http://
genome/ucsc.edu) and Online Mendelian Inheritance in Man
(http://www3.ncbi.nlm.nih.gov/entrez/query.fcgi?db 5 OMIM)
to determine the cytogenetic location of markers and to search for
candidate genes.
Analytical methods
Quantitative analyses. SAS, version 8.0, was used to screen co-
variates for statistical significance using backward- and forward-
stepwise linear regression by center. SOLAR, version 2.1.2, was
used to perform multipoint variance component linkage analysis
of LDL-C among 980 SHFS participants (South Dakota 5 333,
Oklahoma 5 307, Arizona 5 340) (30). Details of this model have
been described previously (30, 31).
The use of the variance component approach requires an es-
timate of the identity-by-descent matrix. We used the Loki
package (32), which uses a Markov chain Monte Carlo stochastic
procedure to compute the identity-by-descent allele sharing at
points throughout the genome conditional on the genotype in-
formation available at neighboring points.
Application to SHFS data. Because we recruited extended
families, the sample of examined individuals included a large
number of relative pair types, including information on 10,380
relative pairs (South Dakota 5 4,260, Oklahoma 5 3,039, Arizona
5 3,081; Table 1). All phenotypic outliers (here defined as any
value .4 standard deviations from the mean) were removed
before analysis (the number excluded varies by analysis; n , 10).
Participants on lipid-lowering medications (13 individuals in
total; North and South Dakota 5 10, Oklahoma 5 2, Arizona 5 1)
were excluded from the analyses.
To maximize our power to detect genetic effects, we con-
sidered two different models of covariate adjustment in each
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population separately. In model 1, adjustments were made for
age, sex, age squared, and age-sex interactions. For model 2,
additional covariates of body mass index, smoking status, alcohol
consumption, estrogen use, diabetes status, impaired fasting glu-
cose, and physical activity were screened for statistical signifi-
cance, and all covariates whose effects were significant at the
P < 0.10 level were retained in subsequent analyses. We addi-
tionally confirmed the significance of model 2 covariates while
accounting for family relationships in SOLAR. Residuals were
generated for both models (model 1 and model 2) and used in all
subsequent genetic analyses. Kurtosis values for LDL-C were
,0.50 for all analyses (33).
To verify the significance of our linkage signals, we calculated
LOD scores under the assumption of multivariate normality and
under the hypothesis of no linkage, using 10,000 replicates and
simulation methods incorporated into SOLAR (30). The empiri-
cal distribution of the simulated LOD scores is used to assign
percentiles to each replicate, calculate an expected test statistic
on the basis of the percentile, and produce a correction constant,
which is used to determine an adjusted LOD score and a cor-
responding P value (34).
Association analysis of APOE polymorphism
An association study of APOE polymorphism and LDL-C
concentrations was performed using both model 1 and model 2
covariate adjustment strategies in the North and South Dakota
population only, as linkage to 19q was specific to the South
Dakota center. A total of 307 participants had complete data on
the APOE polymorphism. We assessed deviations from Hardy-
Weinberg equilibrium using the standard Chi-square test. A mea-
sured genotype approach, incorporating a variance component
to account for linkage, was used to test for association.
RESULTS
The descriptive characteristics of the SHFS participants
are summarized in Table 2. The average age 6 SD of par-
ticipants in each center was z41 6 16, 44 6 15, and 41 6
16 years in South Dakota, Oklahoma, and Arizona, re-
spectively. The SHFS participants were more often female,
and a high prevalence of cigarette smoking and alcohol
consumption was observed. As expected, a high prevalence
of diabetes was noted, especially in the Arizona center.
LDL-C concentrations varied by center and were highest in
the North and South Dakota center (122.06 6 31.98 mg/dl).
In model 1, adjustments were made for age, sex, and
their interactions. In model 2, additional adjustments
were made for significant covariates (P, 0.10): METs and
current and ever smoking status; alcohol consumption
and estrogen use; and METs, ever smoking status, and di-
abetes status in the North and South Dakota, Oklahoma,
and Arizona centers, respectively. The statistical significance
of all model 2 covariates was confirmed after accounting for
the relatedness of family members in SOLAR (P , 0.05). A
QTL for LDL-C (adjusted LOD 5 4.3) was detected in the
South Dakota population on chromosome 19 at 93 cM,
nearest marker D19S888 (19q13.41) (Fig. 1). The 1 LOD
unit support interval spanned 15 cM, from 83 to 98 cM
(52.565–58.985 Mb p terminus).
Table 3 presents the multipoint genome-wide adjusted
LOD scores and their locations from the variance com-
ponent linkage analyses for all peaks >1.8 [suggestive evi-
dence of linkage (35)]. Although no other genome-wide
significant evidence of linkage was detected, suggestive
TABLE 2. Descriptive statistics of Strong Heart Family Study participants by center
Variables Dakotas Oklahoma Arizona
Total number 333 307 340
LDL-C (mg/dl) 122.06 6 31.98 115.48 6 28.37 110.99 6 29.38
Mean age (years 6 SD) 41.29 6 16.31 43.55 6 15.42 41.41 6 16.10
Male [n (%)] 131 (39) 138 (45) 140 (41)
Body mass index (kg/m2; mean 6 SD) 30.21 6 5.95 30.53 6 6.53 35.05 6 8.75
Diabetes [n (%)]a 54 (17) 61 (20) 135 (41)
Impaired fasting glucose [n (%)]a 14 (4) 27 (9) 33 (10)
Ever smoke [n (%)]b 190 (59) 165 (54) 154 (47)
Current smoke [n (%)] 143 (45) 102 (33) 80 (24)
Ever consume alcohol [n (%)]c 243 (76) 225 (74) 257 (78)
Current consume alcohol [n (%)] 204 (64) 137 (45) 196 (60)
Ever estrogen use [n (%)] 33 (10) 41 (13) 24 (8)
Current estrogen use [n (%)] 19 (6) 28 (9) 12 (4)
METs (h/year; mean 6 SD)d 173.93 6 222.98 116.35 6 154.50 90.73 6 124.13
LDL-C, low density lipoprotein cholesterol; MET, metabolic equivalent.
a Diabetes and impaired fasting glucose status were determined using American Diabetes Association criteria.
b Smoking was defined as having had at least 100 cigarettes.
c Alcohol consumption was defined as having had at least one alcoholic beverage.
d 1 MET 5 a resting oxygen consumption of z3.5 ml/kg/min.
TABLE 1. Strong Heart Family Study: numbers of
examined relative pairs
Relationship Dakotas Oklahoma Arizona
Parent-offspring 258 217 218
Siblings 279 285 256
Half siblings 76 70 51
Avuncular 800 727 500
Grandparent-grandchild 86 34 73
Grand avuncular 272 129 168
First cousins 888 776 684
First cousins once removed 695 390 704
Half first cousins 18 72 12
Second cousins 345 58 190
Double first cousins once removed 148 0 0
Double second cousins 112 0 0
Other 283 281 225
Total relative pairs 4,260 3,039 3,081
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evidence of linkage to LDL-C was detected on 3q, 4q, 7p,
9q, 10p, 14q, and 17q. Supplementary Figs. 1–6 display
linkage results for all chromosomes.
We had data on an interesting candidate gene for the 19q
linkage signal, namely the genotypes at the APOE poly-
morphism, which is,2 Mb from the peak linkage signal. We
tested for association between the APOE polymorphism and
LDL-C concentration using the model 1 and model 2 ad-
justment strategies. As a previous study of this population
noted the APOE-sex interaction on circulating lipid levels
(36), all analyses incorporated such interaction. The fre-
quencies of the *e2, *e3, and *e4 alleles of the APOE
gene were 0.02, 0.90, and 0.08, respectively. No deviation
from Hardy-Weinberg equilibrium was detected (P5 0.29).
There were no individuals homozygous for the *e2 allele.
For genetic analysis, an additive model was used, and two
dummy variables to encode for the number of rare *e2 al-
leles and *e4 alleles were considered. No significant asso-
ciation between the APOE polymorphism and LDL-C was
found (P 5 0.76 and P 5 0.53 for the *e2 and *e4 alleles,
respectively), and when forced into the model, ,1% of the
residual phenotypic variation of LDL-C was accounted for by
the APOE polymorphism.
DISCUSSION
In our previous work, we demonstrated a substantial
genetic component of variation in LDL-C (8). The present
study was undertaken to identify regions of the genome
harboring genes that influence LDL-C. Here, we present
evidence for a QTL for LDL-C (adjusted LOD 5 4.3) in the
North and South Dakota population on chromosome 19,
nearest marker D19S888. Three large families in the South
Dakota population contribute substantially to the overall
LOD score (consisting of 263 phenotyped individuals com-
prising 3,884 relative pairs) and include the majority of
participants from the South Dakota center. No substantial
LOD scores were obtained in the samples from Arizona
and Oklahoma in this region (19q), potentially indicat-
ing genetic heterogeneity among the different American
Indian samples at this locus.
Fig. 1. Multipoint adjusted LOD scores on chro-
mosome 19 for LDL cholesterol. Model 1 was ad-
justed for age, sex, age squared, and age-sex
interaction in all centers. Model 2 in the Dakotas
(DA) was additionally adjusted for metabolic equiva-
lents (METs), ever smoking, and current smoking.
Model 2 in Arizona (AZ) was additionally adjusted
for METs, diabetes status, and ever smoking. Model
2 in Oklahoma (OK) was additionally adjusted for
current alcohol consumption and current estrogen
use. cM, centimorgan.
TABLE 3. Adjusted LOD scores suggestive of linkage (LOD > 1.8) using two modeling strategies for multipoint
quantitative trait linkage analyses of LDL-C
Center and Model Chromosome Centimorgan Chromosomal Region
Empirical
LOD Score
Oklahoma, model 1a 3 200 3q26.2 – q26.31 1.8
Dakotas, model 1a 4 78 4q12 1.8
Dakotas, model 2b 4 154 4q31.21 2.5
Dakotas, model 1a model 2b 7 47 7p15.1 2.6, 2.3
Arizona, model 1a model 2c 9 150–151 9q34.11 1.9, 2.1
Arizona, model 1a model 2c 10 13–15 10p15.1 2.3, 2.8
Dakotas, model 1a model 2b 14 130–131 14q32.2 2.6, 2.3
Arizona, model 1a 17 90 17q23.3 2.5
Oklahoma, model 1a model 2d 17 132 17q25.3 2.1
Dakotas, model 1a model 2b 19 93 19q13.41 4.3, 2.7
Linkage significance criteria were as suggested by Rao and Gu (35).
a Model 1 was adjusted for age, sex, age squared, and age-sex interaction in all centers.
b Model 2 in the Dakotas was additionally adjusted for METs, ever smoking, and current smoking.
c Model 2 in Arizona was additionally adjusted for METs, diabetes status, and ever smoking.
d Model 2 in Oklahoma was additionally adjusted for current alcohol consumption and current estrogen use.
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Chromosome 19q, where we observe our strongest link-
age evidence, has previously been implicated in six ge-
nome scans of lipid-related traits (37–42). Genome-wide
significant LOD scores were reported in this region for
LDL-C among participants from the Quebec Family Study
(LOD 5 3.6) (40), for LDL-C among adolescent Dutch,
Swedish, and Australian twins (LOD 5 5.7) (39), for tri-
glyceride concentrations in large extended families from
Utah (LOD 5 3.2) (42), and for apoE in participants from
the Rochester Heart Study (LOD 5 4.2) (41). Suggestive
linkage has also been noted for LDL-C in Hutterite family
members (P 5 0.0001) (39) and for LDL particle size in
Mexican-American participants of the San Antonio Family
Heart Study (1.9 < LOD < 2.3) (38).
When additionally adjusting LDL-C for current smoking,
ever smoking, and METs, the magnitude of the LOD score
on chromosome 19q decreased by 1.6 units, yet it still
provided suggestive evidence for linkage (adjusted LOD 5
2.7). These reductions are partially related to the individuals
who were removed from analyses when including these
additional covariates in model 2 (n 5 25 exclusions for
missing covariate data). For example, when model 1 is re-
stricted to the same sample of individuals included in model
2, the adjusted LOD score of model 1 decreases from 4.3 to
3.6. Thus, the LOD score of model 2 (2.7) is still reduced by
0.9 LOD compared with the LOD score of model 1 (3.6)
obtained when analyzing the exact same sample of indi-
viduals with different adjustment strategies. It is possible that
the measures of physical activity and smoking status have
shared genetic effects with LDL-C. Previous studies have
supported a significant genetic influence on smoking and
physical activity (43, 44), and we have observed significant
[h2 (heritability) current smoking 5 0.16 6 0.11 (P 5
0.023); h2 ever smoking 5 0.21 6 0.11 (P 5 0.01)] and
suggestive [h2 METs 5 0.10 6 0.09 (P5 0.06)] heritabilities
in this population as well. Moreover, a significant genetic
correlation between METs and LDL-C was detected [rG
(genetic correlation) 5 0.87 6 0.48; P 5 0.048], which
indicates shared genetic effects between these two traits.
Thus, to the extent that there are pleiotropic effects of
genes on METs and LDL-C, the evidence for linkage will be
reduced when adjusting for these covariates. Nonetheless,
although the LOD score decreases, we find suggestive
evidence for linkage on chromosome 19, which offers strong
support for the presence of a lipid-related QTL on chro-
mosome 19 and suggests the robustness of this signal.
Moreover, our results show a high degree of overlap with
other studies and may indeed provide probable locations
for candidate gene follow-up studies.
Approximately 142 known genes underlie the 1 LOD
unit decrease support interval (15 cM, 7.5 Mb) of the 19q
signal. The most logical candidate genes are locatedz2 Mb
from our highest LOD score, the APOE/C1/C4/C2 gene
cluster. ApoE is the major constituent of chylomicrons and
VLDL and serves as a ligand for LDL receptors (45). The
APOE gene has three common alleles, APOE*e2, *e3, and
*e4, that code for three major isoforms that vary in their
affinity for receptor binding (13). Thus, carriers of the *e2
allele (which has a dramatically reduced affinity for
binding) are less efficient at making and transferring
VLDLs and chylomicrons from the blood to the liver and
thus are slower to take up postprandial lipoprotein par-
ticles compared with *e3 and *e4 carriers. These APOE
genetic variants have been associated with LDL variation
across multiple populations (12, 13) as well as with other
lipid-related traits, such as triglyceride concentration (46).
In addition, interactions between the APOE polymor-
phisms and environmental modulators, such as nutrient
intake (14, 47), sex (48), age (49), smoking behavior (49),
alcohol consumption (50), and type 2 diabetes (49), have
all been indicated. Moreover, other relevant polymor-
phisms in the APOE gene promoter region (2219G/T and
1113G/C) have also been evaluated, although the findings
from these studies have been inconsistent (15–18).
In this study, no association of APOE polymorphism with
LDL-C was found. This result is contrary to previous work
in the SHS, which reported an association of the APOE
polymorphism with LDL-C. However, the previous study
by Kataoka et al. (37) examined the original, mostly un-
related SHS participants across all three subpopulations
(n 5 4,541), of which only a small fraction are included in
the SHFS sample (n 5 64). Moreover, the sample of in-
dividuals examined is much smaller in our study (n 5 307
with APOE data) because the linkage signal was specific to
the South Dakota center only. Regardless of these factors,
the APOE polymorphism cannot account for the observed
linkage of variation in LDL-C levels to 19q. This suggests
that there are other important variants in the APOE gene
or in other nearby genes that influence variation in LDL-C.
As mentioned above, APOE is located within an exciting
cluster of genes (APOE/C1/C4/C2) that are likely relevant
to circulating lipid levels.
One such likely candidate is the apoC-I gene. ApoC-I is a
constituent of VLDL and HDL and inhibits the binding of
VLDL to LDL-related protein (51) as well as the APOE-
mediated binding of VLDL to the LDL receptor (52),
leading to reduced levels of LDL-C (53). Rare APOC1 vari-
ants and the common HpaI restriction fragment-length
polymorphism promoter polymorphism have been associ-
ated with triglyceride concentrations (54, 55), although
the findings have been inconsistent (56). ApoC-II operates
to activate lipoprotein lipase and leads to increased levels
of LDL-C (57). APOC2 variants have been associated with
total cholesterol and LDL-C levels in Nigerians (58) but not
in African-Americans (59). The exact function of apoC-IV
is unknown, although it appears to play a role in lipid me-
tabolism (60). The Leu36Pro and Leu96Arg APOC4 vari-
ants have been associated with triglyceride concentrations
in white women (61). Overall, the association of lipid-
related traits with variants in the APOE/C1/C4/C2 gene
cluster has been fairly inconsistent, with the exception of
the APOE gene variants. Such inconsistency is possibly
related to the close linkage of these genes on chromosome
19q. Strong linkage disequilibrium between APOC1 and
APOE variants has been reported in the literature (54, 56);
thus, the interpretation of findings with single polymor-
phisms is extremely difficult, given the disparate effects of
these polymorphisms in the lipid pathway. Future research
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should involve resequencing the genes in this cluster to
catalog the full extent of genetic variation present in this
population and to identify the functional polymorphisms
responsible for the observed linkage signal.
We also observed several loci with suggestive linkage to
LDL-C, some novel and others supporting positive find-
ings from other studies. Table 4 summarizes the observed
linkage signals from this study that are supported by evi-
dence of linkage to lipid-related traits in other popula-
tions on 3q, 4q, 7p, 9q, 10p, 14q, and 17q. Although these
signals do not meet the genome-wide significance thresh-
old, these results still offer valuable information in that
they may identify regions worthy of further study and
help to distinguish between true- and false-positives. For
example, although we detect suggestive linkage to LDL on
chromosome 17q in the Oklahoma center, this signal is
robust to adjustment for covariates (Table 4) and has
been implicated in at least four other lipid-related genome
scans (9, 41, 62, 63).
Conclusions
In conclusion, our findings suggest that one or more
genes on chromosome 19q regulate LDL-C concentration.
This region harbors the APOE/C1/C4/C2 gene cluster, an
excellent candidate for LDL-C variability because of its
accepted role in lipid metabolism. Future research should
pursue these positional candidate genes to determine
whether polymorphisms in these genes are the source of
this highly replicated linkage signal.
Our study also provides corroboration of genomic
regions that possibly influence interindividual variation
in LDL-C concentrations on chromosomes 3q, 4q, 7p, 9q,
and 17q and new information about genomic regions on
10p and 14q. The identification and confirmation of QTLs
for LDL-C will bring us closer to the identification of the
functional genes that influence LDL-C and aid in disen-
tangling the complex causes of cardiovascular disease.
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LDL-PPD 2.6 Badzioch et al. (65)
Dakotas, model 1a model 2 2.6, 2.3 7p15.1 Triglycerides 2.1 Duggirala et al. (66)
ApoB 2.0 Feitosa et al. (21)
Arizona, model 1a model 2c 1.9, 2.1 9q34.11 LDL-PPD 1.3 Bosse et al. (64)
CHOL 1.6 Pollin et al. (67)
Arizona, model 1a 2.5 17q23.3 LDL-C 2.3 Broeckel et al. (68)
Oklahoma, model 1a model 2d 2.1 17q25.3 CHOL/HDL-C 2.5 Klos et al. (41)
LDL-C 2.3 Coon et al. (9)
FH 2.7 Hunt et al. (62)
LDL-PPD 1.1 , LOD , 6.8 Bosse et al. (63)
Dakotas, model 1a model 2 4.3, 2.7 19q13.41 LDL-C P 5 0.0001 Ober, Abney, and McPeek (38)
LDL-C 3.6 Bosse et al. (19)
ApoE 4.2 Klos et al. (41)
Triglycerides 3.2 Elbein and Hasstedt (42)
LDL-1, LDL-2 2.3, 1.9 Rainwater et al. (38)
LDL-C 5.7 Beekman et al. (37)
Linkage criteria were as suggested by Rao and Gu (35). Apo, apolipoprotein; CHOL, total serum cholesterol; FH, familial hypercholesterolemia;
HDL-C, high density lipoprotein cholesterol; LDL-PPD, low density lipoprotein peak particle diameter; LDL-1, -2, and -3, cholesterol concentration
in three LDL size fractions.
a Model 1 was adjusted for age, sex, age squared, and age-sex interaction in all centers.
b Model 2 in the Dakotas was additionally adjusted for METs, ever smoking, and current smoking.
c Model 2 in Arizona was additionally adjusted for METs, diabetes status, and ever smoking.
d Model 2 in Oklahoma was additionally adjusted for current alcohol consumption and current estrogen use.
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